

E Michael Lewiecki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8151558/publications.pdf>

Version: 2024-02-01

262
papers

18,701
citations

14614

66
h-index

13727

129
g-index

294
all docs

294
docs citations

294
times ranked

13367
citing authors

#	ARTICLE	IF	CITATIONS
1	Denosumab in Postmenopausal Women with Low Bone Mineral Density. <i>New England Journal of Medicine</i> , 2006, 354, 821-831.	13.9	1,107
2	Romosozumab Treatment in Postmenopausal Women with Osteoporosis. <i>New England Journal of Medicine</i> , 2016, 375, 1532-1543.	13.9	1,099
3	Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial. <i>Bone</i> , 2008, 43, 222-229.	1.4	495
4	American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis 2020 Update. <i>Endocrine Practice</i> , 2020, 26, 1-46.	1.1	493
5	American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis 2016-Executive Summary. <i>Endocrine Practice</i> , 2016, 22, 1111-1118.	1.1	453
6	Presentation of Asymptomatic Primary Hyperparathyroidism: Proceedings of the Third International Workshop. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 351-365.	1.8	451
7	Clinical Use of Quantitative Computed Tomography and Peripheral Quantitative Computed Tomography in the Management of Osteoporosis in Adults: The 2007 ISCD Official Positions. <i>Journal of Clinical Densitometry</i> , 2008, 11, 123-162.	0.5	430
8	Bisphosphonate Therapy for Osteoporosis: Benefits, Risks, and Drug Holiday. <i>American Journal of Medicine</i> , 2013, 126, 13-20.	0.6	408
9	Official Positions of the International Society for Clinical Densitometry and Executive Summary of the 2007 ISCD Position Development Conference. <i>Journal of Clinical Densitometry</i> , 2008, 11, 75-91.	0.5	379
10	American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis 2016. <i>Endocrine Practice</i> , 2016, 22, 1-42.	1.1	377
11	Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. <i>Osteoporosis International</i> , 2017, 28, 1-19.	1.3	376
12	Quantitative Ultrasound in the Management of Osteoporosis: The 2007 ISCD Official Positions. <i>Journal of Clinical Densitometry</i> , 2008, 11, 163-187.	0.5	322
13	Current Issues in the Presentation of Asymptomatic Primary Hyperparathyroidism: Proceedings of the Fourth International Workshop. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3580-3594.	1.8	318
14	Monthly Oral Ibandronate Therapy in Postmenopausal Osteoporosis: 1-Year Results From the MOBILE Study. <i>Journal of Bone and Mineral Research</i> , 2005, 20, 1315-1322.	3.1	288
15	Executive Summary of the 2019 ISCD Position Development Conference on Monitoring Treatment, DXA Cross-calibration and Least Significant Change, Spinal Cord Injury, Peri-prosthetic and Orthopedic Bone Health, Transgender Medicine, and Pediatrics. <i>Journal of Clinical Densitometry</i> , 2019, 22, 453-471.	0.5	284
16	Official Positions of the International Society for Clinical Densitometry. <i>Journal of Clinical Densitometry</i> , 2004, 7, 1-5.	0.5	282
17	Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD. <i>Journal of Bone and Mineral Research</i> , 2007, 22, 1832-1841.	3.1	282
18	Early Changes in Biochemical Markers of Bone Formation Predict BMD Response to Teriparatide in Postmenopausal Women With Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2005, 20, 962-970.	3.1	280

#	ARTICLE	IF	CITATIONS
19	Precision Assessment and Radiation Safety for Dual-Energy X-Ray Absorptiometry. <i>Journal of Clinical Densitometry</i> , 2005, 8, 371-378.	0.5	260
20	Official Positions of the International Society for Clinical Densitometry. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 3651-3655.	1.8	242
21	Benefits and Risks of Bisphosphonate Therapy for Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 2272-2282.	1.8	238
22	Best Practices for Dual-Energy X-ray Absorptiometry Measurement and Reporting: International Society for Clinical Densitometry Guidance. <i>Journal of Clinical Densitometry</i> , 2016, 19, 127-140.	0.5	214
23	Effects of Bazedoxifene on BMD and Bone Turnover in Postmenopausal Women: 2-Yr Results of a Randomized, Double-Blind, Placebo-, and Active-Controlled Study. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 525-535.	3.1	207
24	Vertebral Fractures: Clinical Importance and Management. <i>American Journal of Medicine</i> , 2016, 129, 221.e1-221.e10.	0.6	204
25	Hip fracture trends in the United States, 2002 to 2015. <i>Osteoporosis International</i> , 2018, 29, 717-722.	1.3	198
26	The Pathophysiology and Treatment of Osteoporosis. <i>Clinical Therapeutics</i> , 2015, 37, 1837-1850.	1.1	196
27	A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 3183-3193.	1.8	195
28	Effects of Intravenous Zoledronic Acid Once Yearly on Bone Remodeling and Bone Structure. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 6-16.	3.1	189
29	National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): What They Mean to the Bone Densitometrist and Bone Technologist. <i>Journal of Clinical Densitometry</i> , 2008, 11, 473-477.	0.5	183
30	A Randomized, Placebo-Controlled Study of the Effects of Denosumab for the Treatment of Men with Low Bone Mineral Density. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3161-3169.	1.8	179
31	Clinical Applications of Vertebral Fracture Assessment by Dual-Energy X-Ray Absorptiometry. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 4215-4222.	1.8	176
32	Observations following discontinuation of long-term denosumab therapy. <i>Osteoporosis International</i> , 2017, 28, 1723-1732.	1.3	174
33	Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: A multicenter, randomized, open-label, crossover study. <i>Clinical Therapeutics</i> , 2002, 24, 1871-1886.	1.1	162
34	Skeletal health in long-duration astronauts: Nature, assessment, and management recommendations from the NASA bone summit. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 1243-1255.	3.1	139
35	Official Positions of the International Society for Clinical Densitometry and Executive Summary of the 2005 Position Development Conference. <i>Journal of Clinical Densitometry</i> , 2006, 9, 4-14.	0.5	134
36	Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: Six-Year Results of a Phase 2 Clinical Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 394-402.	1.8	131

#	ARTICLE	IF	CITATIONS
37	Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2014, 6, 48-57.	1.2	128
38	Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 3-10.	3.1	127
39	Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 1480-1486.	3.1	126
40	One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 419-428.	3.1	126
41	New targets for intervention in the treatment of postmenopausal osteoporosis. <i>Nature Reviews Rheumatology</i> , 2011, 7, 631-638.	3.5	116
42	Vertebral Fracture Assessment: The 2005 ISCD Official Positions. <i>Journal of Clinical Densitometry</i> , 2006, 9, 37-46.	0.5	111
43	Recalculation of the NHANES Database SD Improves T-Score Agreement and Reduces Osteoporosis Prevalence. <i>Journal of Bone and Mineral Research</i> , 2004, 20, 195-201.	3.1	108
44	American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis—2020 Update Executive Summary. <i>Endocrine Practice</i> , 2020, 26, 564-570.	1.1	108
45	A 24-Month Study Evaluating the Efficacy and Safety of Denosumab for the Treatment of Men With Low Bone Mineral Density: Results From the ADAMO Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1335-1342.	1.8	105
46	Standards and Guidelines for Performing Central Dual-Energy X-Ray Absorptiometry in Premenopausal Women, Men, and Children—A Report From the Canadian Panel of the International Society of Clinical Densitometry. <i>Journal of Clinical Densitometry</i> , 2004, 7, 51-63.	0.5	101
47	Denosumab for the treatment of osteoporosis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 461-470.	1.5	101
48	Healthcare Policy Changes in Osteoporosis Can Improve Outcomes and Reduce Costs in the United States. <i>JBMR Plus</i> , 2019, 3, e10192.	1.3	97
49	Rosiglitazone Decreases Bone Mineral Density and Increases Bone Turnover in Postmenopausal Women With Type 2 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 1519-1528.	1.8	92
50	Nonresponders to Osteoporosis Therapy. <i>Journal of Clinical Densitometry</i> , 2003, 6, 307-314.	0.5	90
51	Efficacy and safety of monthly ibandronate in men with low bone density. <i>Bone</i> , 2010, 46, 970-976.	1.4	89
52	Once-Monthly Oral Ibandronate Improves Biomechanical Determinants of Bone Strength in Women with Postmenopausal Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 171-180.	1.8	86
53	Effects of Atorvastatin on Bone in Postmenopausal Women with Dyslipidemia: A Double-Blind, Placebo-Controlled, Dose-Ranging Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4671-4677.	1.8	85
54	Safety of Bisphosphonates in the Treatment of Osteoporosis. <i>American Journal of Medicine</i> , 2009, 122, S22-S32.	0.6	84

#	ARTICLE	IF	CITATIONS
55	Bisphosphonates for the treatment of osteoporosis: insights for clinicians. <i>Therapeutic Advances in Chronic Disease</i> , 2010, 1, 115-128.	1.1	84
56	Joint Official Positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX [®] . <i>Journal of Clinical Densitometry</i> , 2011, 14, 171-180.	0.5	82
57	Skeletal Histomorphometry in Subjects on Teriparatide or Zoledronic Acid Therapy (SHOTZ) Study: A Randomized Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 2799-2808.	1.8	79
58	Relationship Between Bone Mineral Density T-Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 1033-1040.	3.1	79
59	Romosozumab for the treatment of osteoporosis. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 255-263.	1.4	78
60	Safety of Long-Term Bisphosphonate Therapy for the Management of Osteoporosis. <i>Drugs</i> , 2011, 71, 791-814.	4.9	75
61	Dual-energy X-ray Absorptiometry Monitoring with Trabecular Bone Score: 2019 ISCD Official Position. <i>Journal of Clinical Densitometry</i> , 2019, 22, 501-505.	0.5	73
62	Skeletal Effects of Primary Hyperparathyroidism: Bone Mineral Density and Fracture Risk. <i>Journal of Clinical Densitometry</i> , 2013, 16, 28-32.	0.5	72
63	Clinical use of serum and urine bone markers in the management of osteoporosis. <i>Current Medical Research and Opinion</i> , 2005, 21, 1015-1026.	0.9	71
64	Peripheral Dual-Energy X-ray Absorptiometry in the Management of Osteoporosis: The 2007 ISCD Official Positions. <i>Journal of Clinical Densitometry</i> , 2008, 11, 188-206.	0.5	71
65	Suicide, Guns, and Public Policy. <i>American Journal of Public Health</i> , 2013, 103, 27-31.	1.5	71
66	Hypophosphatasia in Adults: Clinical Assessment and Treatment Considerations. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 1977-1980.	3.1	67
67	Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts' consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation. <i>Osteoporosis International</i> , 2019, 30, 45-57.	1.3	67
68	DXA Quality Matters. <i>Journal of Clinical Densitometry</i> , 2006, 9, 388-392.	0.5	66
69	Special report on the official positions of the International Society for Clinical Densitometry. <i>Osteoporosis International</i> , 2004, 15, 779-84.	1.3	64
70	Osteoporosis in Crisis: It's Time to Focus on Fracture. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 1391-1394.	3.1	64
71	Treat-to-target for Osteoporosis: Is Now the Time?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 946-953.	1.8	63
72	Remodeling- and Modeling-Based Bone Formation With Teriparatide Versus Denosumab: A Longitudinal Analysis From Baseline to 3 Months in the AVA Study. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 298-306.	3.1	63

#	ARTICLE	IF	CITATIONS
73	Bone Densitometry and Vertebral Fracture Assessment. <i>Current Osteoporosis Reports</i> , 2010, 8, 123-130.	1.5	62
74	Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. <i>Bone</i> , 2007, 40, 843-851.	1.4	59
75	Clinical Value of Monitoring BMD in Patients Treated With Bisphosphonates for Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 1643-1646.	3.1	58
76	American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis—2020 Update. <i>Endocrine Practice</i> , 2021, 27, 379-380.	1.1	57
77	New and emerging concepts in the use of denosumab for the treatment of osteoporosis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2018, 10, 209-223.	1.2	56
78	Romsozumab FRAME Study: A Post Hoc Analysis of the Role of Regional Background Fracture Risk on Nonvertebral Fracture Outcome. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 1407-1416.	3.1	56
79	Common mistakes in the clinical use of bone mineral density testing. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 667-674.	3.2	55
80	Goal-directed treatment of osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 433-438.	3.1	54
81	Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1353-1363.	1.8	52
82	Prevention and Treatment of Postmenopausal Osteoporosis. <i>Obstetrics and Gynecology Clinics of North America</i> , 2008, 35, 301-315.	0.7	48
83	Treatment of osteoporosis with denosumab. <i>Maturitas</i> , 2010, 66, 182-186.	1.0	48
84	RANK ligand inhibition with denosumab for the management of osteoporosis. <i>Expert Opinion on Biological Therapy</i> , 2006, 6, 1041-1050.	1.4	47
85	Review of guidelines for bone mineral density testing and treatment of osteoporosis. <i>Current Osteoporosis Reports</i> , 2005, 3, 75-83.	1.5	46
86	Current and Emerging Pharmacologic Therapies for the Management of Postmenopausal Osteoporosis. <i>Journal of Women's Health</i> , 2009, 18, 1615-1626.	1.5	46
87	A Longitudinal Study of Skeletal Histomorphometry at 6 and 24 Months Across Four Bone Envelopes in Postmenopausal Women With Osteoporosis Receiving Teriparatide or Zoledronic Acid in the SHOTZ Trial. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 1429-1439.	3.1	46
88	Effects of Denosumab on the Geometry of the Proximal Femur in Postmenopausal Women in Comparison with Alendronate. <i>Journal of Clinical Densitometry</i> , 2008, 11, 351-359.	0.5	45
89	Official Positions for FRAX® Bone Mineral Density and FRAX® Simplification. <i>Journal of Clinical Densitometry</i> , 2011, 14, 226-236.	0.5	45
90	Denosumab update. <i>Current Opinion in Rheumatology</i> , 2009, 21, 369-373.	2.0	44

#	ARTICLE	IF	CITATIONS
91	Renal safety of intravenous bisphosphonates in the treatment of osteoporosis. Expert Opinion on Drug Safety, 2007, 6, 663-672.	1.0	43
92	Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis. International Journal of Women's Health, 2015, 7, 565.	1.1	43
93	Bone density testing in clinical practice. Arquivos Brasileiros De Endocrinologia E Metabologia, 2006, 50, 586-595.	1.3	41
94	Tumor–induced osteomalacia: Lessons learned. Arthritis and Rheumatism, 2008, 58, 773-777.	6.7	40
95	Risk Communication and Shared Decision Making in the Care of Patients With Osteoporosis. Journal of Clinical Densitometry, 2010, 13, 335-345.	0.5	40
96	Prevalence and Cost of Subsequent Fractures Among U.S. Patients with an Incident Fracture. Journal of Managed Care & Specialty Pharmacy, 2017, 23, 461-471.	0.5	39
97	Romosozumab and antiresorptive treatment: the importance of treatment sequence. Osteoporosis International, 2022, 33, 1243-1256.	1.3	38
98	Management of osteoporosis. , 2004, 2, 9.		37
99	A Review of Strontium Ranelate and Its Effect on DXA Scans. Journal of Clinical Densitometry, 2007, 10, 113-119.	0.5	37
100	More bone density testing is needed, not less. Journal of Bone and Mineral Research, 2012, 27, 739-742.	3.1	37
101	Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis. Expert Opinion on Biological Therapy, 2011, 11, 117-127.	1.4	36
102	New Guidelines for the Prevention and Treatment of Osteoporosis. Southern Medical Journal, 2009, 102, 175-179.	0.3	36
103	Standards for Performing DXA in Individuals With Secondary Causes of Osteoporosis. Journal of Clinical Densitometry, 2006, 9, 47-57.	0.5	35
104	Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis. Menopause, 2013, 20, 130-137.	0.8	35
105	Consensus Statement on the Use of Bone Turnover Markers for Short-Term Monitoring of Osteoporosis Treatment in the Asia-Pacific Region. Journal of Clinical Densitometry, 2021, 24, 3-13.	0.5	35
106	Osteoporotic fracture trends in a population of US managed care enrollees from 2007 to 2017. Osteoporosis International, 2020, 31, 1299-1304.	1.3	33
107	The Official Positions of the International Society for Clinical Densitometry: Perceptions and Commentary. Journal of Clinical Densitometry, 2009, 12, 267-271.	0.5	32
108	Assessing the Effects of Teriparatide Treatment on Bone Mineral Density, Bone Microarchitecture, and Bone Strength. Journal of Bone and Joint Surgery - Series A, 2014, 96, e90.	1.4	32

#	ARTICLE	IF	CITATIONS
109	Challenges in osteoporosis awareness and management: results from a survey of US postmenopausal women. <i>Journal of Drug Assessment</i> , 2019, 8, 25-31.	1.1	32
110	Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 1333-1342.	3.1	32
111	Adherence to and Gastrointestinal Tolerability of Monthly Oral or Quarterly Intravenous Ibandronate Therapy in Women with Previous Intolerance to Oral Bisphosphonates: A 12-Month, Open-Label, Prospective Evaluation. <i>Clinical Therapeutics</i> , 2008, 30, 605-621.	1.1	31
112	Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis. <i>Drug, Healthcare and Patient Safety</i> , 2011, 3, 79.	1.0	31
113	Pharmacodynamics and pharmacokinetics of oral salmon calcitonin in the treatment of osteoporosis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 681-689.	1.5	31
114	Report of the International Society for Clinical Densitometry 2007 Adult Position Development Conference and Official Positions. <i>Southern Medical Journal</i> , 2008, 101, 735-739.	0.3	30
115	Update on romosozumab: a humanized monoclonal antibody to sclerostin. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 697-707.	1.4	30
116	Premenopausal bone health assessment. <i>Current Rheumatology Reports</i> , 2005, 7, 46-52.	2.1	29
117	Adverse effects of media reports on the treatment of osteoporosis. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 1359-1364.	1.8	29
118	Sclerostin and skeletal health. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2015, 16, 149-156.	2.6	28
119	Managing osteoporosis: Challenges and strategies. <i>Cleveland Clinic Journal of Medicine</i> , 2009, 76, 457-466.	0.6	27
120	Telementoring: a novel approach to reducing the osteoporosis treatment gap. <i>Osteoporosis International</i> , 2017, 28, 407-411.	1.3	27
121	Repeating Measurement of Bone Mineral Density when Monitoring with Dual-energy X-ray Absorptiometry: 2019 ISCD Official Position. <i>Journal of Clinical Densitometry</i> , 2019, 22, 489-500.	0.5	27
122	Benefits and Limitations of Bone Mineral Density and Bone Turnover Markers to Monitor Patients Treated for Osteoporosis. <i>Current Osteoporosis Reports</i> , 2010, 8, 15-22.	1.5	25
123	Bone Health ECHO: Telementoring to Improve Osteoporosis Care. <i>Women's Health</i> , 2016, 12, 79-81.	0.7	25
124	Project ECHO. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 303-314.	0.8	25
125	Bazedoxifene and bazedoxifene combined with conjugated estrogens for the management of postmenopausal osteoporosis. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 1663-1672.	1.9	24
126	Denosumab: an investigational drug for the management of postmenopausal osteoporosis. <i>Biologics: Targets and Therapy</i> , 2008, 2, 645.	3.0	24

#	ARTICLE	IF	CITATIONS
127	International Society for Clinical Densitometry Official Positions: Asia-Pacific Region Consensus. <i>Journal of Clinical Densitometry</i> , 2010, 13, 346-351.	0.5	24
128	Safety Observations With 3 Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab During the Randomized FREEDOM Trial and Subjects Who Crossed Over to Denosumab During the FREEDOM Extension. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 1481-1485.	3.1	24
129	Emerging drugs for postmenopausal osteoporosis. <i>Expert Opinion on Emerging Drugs</i> , 2009, 14, 129-144.	1.0	23
130	Leveraging Scarce Resources With Bone Health TeleECHO to Improve the Care of Osteoporosis. <i>Journal of the Endocrine Society</i> , 2017, 1, 1428-1434.	0.1	23
131	Abaloparatide is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared with Teriparatide. <i>Calcified Tissue International</i> , 2018, 103, 540-545.	1.5	23
132	Osteoporosis Update From the 2010 Santa Fe Bone Symposium. <i>Journal of Clinical Densitometry</i> , 2011, 14, 1-21.	0.5	22
133	Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study. <i>Archives of Osteoporosis</i> , 2018, 13, 85.	1.0	22
134	Treated Osteoporosis Is Still Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 605-606.	3.1	21
135	Uses and misuses of quantitative ultrasonography in managing osteoporosis. <i>Cleveland Clinic Journal of Medicine</i> , 2006, 73, 742-746.	0.6	21
136	Western Osteoporosis Alliance Clinical Practice Series: Evaluating the Balance of Benefits and Risks of Long-Term Osteoporosis Therapies. <i>American Journal of Medicine</i> , 2017, 130, 862.e1-862.e7.	0.6	20
137	DXA: 30 years and counting. <i>Bone</i> , 2017, 104, 1-3.	1.4	20
138	FRAX® Bone Mineral Density Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference. <i>Journal of Clinical Densitometry</i> , 2011, 14, 223-225.	0.5	19
139	Repeating Vertebral Fracture Assessment: 2019 ISCD Official Position. <i>Journal of Clinical Densitometry</i> , 2019, 22, 484-488.	0.5	19
140	Vertebral Fracture Assessment by Dual-Energy X-ray Absorptiometry: Insurance Coverage Issues in the United States A White Paper of the International Society for Clinical Densitometry. <i>Journal of Clinical Densitometry</i> , 2007, 10, 227-238.	0.5	18
141	Conjugated estrogens combined with bazedoxifene: the first approved tissue selective estrogen complex therapy. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 281-291.	1.3	18
142	Global epidemiology of hip fractures: a study protocol using a common analytical platform among multiple countries. <i>BMJ Open</i> , 2021, 11, e047258.	0.8	18
143	Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling. <i>IDrugs: the Investigational Drugs Journal</i> , 2009, 12, 799-809.	0.7	18
144	Update on bone density testing. <i>Current Osteoporosis Reports</i> , 2005, 3, 136-142.	1.5	17

#	ARTICLE	IF	CITATIONS
145	Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis. <i>Therapeutics and Clinical Risk Management</i> , 2009, 5, 817.	0.9	17
146	2009 Santa Fe Bone Symposium. <i>Journal of Clinical Densitometry</i> , 2010, 13, 1-9.	0.5	17
147	Understanding and Communicating the Benefits and Risks of Denosumab, Raloxifene, and Teriparatide for the Treatment of Osteoporosis. <i>Journal of Clinical Densitometry</i> , 2014, 17, 490-495.	0.5	17
148	Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3450-3461.	1.8	17
149	Bone Health TeleECHO: a Force Multiplier to Improve the Care of Skeletal Diseases in Underserved Communities. <i>Current Osteoporosis Reports</i> , 2019, 17, 474-482.	1.5	17
150	Management of Skeletal Health in Patients With Asymptomatic Primary Hyperparathyroidism. <i>Journal of Clinical Densitometry</i> , 2010, 13, 324-334.	0.5	16
151	Monoclonal antibodies for the treatment of osteoporosis. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 183-196.	1.4	16
152	Osteoporosis: Treat-to-Target. <i>Current Osteoporosis Reports</i> , 2017, 15, 103-109.	1.5	16
153	Emerging anabolic agents in the treatment of osteoporosis. <i>Expert Opinion on Emerging Drugs</i> , 2017, 22, 247-257.	1.0	16
154	Detection of Atypical Femur Fractures. <i>Journal of Clinical Densitometry</i> , 2019, 22, 506-516.	0.5	16
155	The Rare Bone Disease TeleECHO Program: Leveraging Telehealth to Improve Rare Bone Disease Care. <i>Current Osteoporosis Reports</i> , 2020, 18, 344-349.	1.5	16
156	Official positions of the International Society for Clinical Densitometry. <i>Osteoporosis International</i> , 2006, 17, 1700-1701.	1.3	15
157	Standards and Guidelines for Technologists Performing Central Dual-Energy X-Ray Absorptiometry. <i>Journal of Clinical Densitometry</i> , 2007, 10, 189-195.	0.5	15
158	Algorithm for the Management of Osteoporosis. <i>Southern Medical Journal</i> , 2010, 103, 1009-1017.	0.3	15
159	Clinical use of denosumab for the treatment for postmenopausal osteoporosis. <i>Current Medical Research and Opinion</i> , 2010, 26, 2807-2812.	0.9	15
160	Western Osteoporosis Alliance Clinical Practice Series: Treat-to-Target for Osteoporosis. <i>American Journal of Medicine</i> , 2019, 132, e771-e777.	0.6	15
161	Racial disparities, FRAX, and the care of patients with osteoporosis. <i>Osteoporosis International</i> , 2020, 31, 2069-2071.	1.3	15
162	Teriparatide: Label changes and identifying patients for long-term use. <i>Cleveland Clinic Journal of Medicine</i> , 2021, 88, 489-493.	0.6	15

#	ARTICLE	IF	CITATIONS
163	Evidence-Based Medicine, Clinical Practice Guidelines, and Common Sense in the Management of Osteoporosis. <i>Endocrine Practice</i> , 2009, 15, 573-579.	1.1	15
164	Official Positions of the International Society for Clinical Densitometry. <i>Southern Medical Journal</i> , 2004, 97, 107-110.	0.3	14
165	The Role of Risk Communication in the Care of Osteoporosis. <i>Current Osteoporosis Reports</i> , 2011, 9, 141-148.	1.5	14
166	Osteoporosis Update From the 2012 Santa Fe Bone Symposium. <i>Journal of Clinical Densitometry</i> , 2013, 16, 584-600.	0.5	14
167	Consensus on best practice standards for Fracture Liaison Service in the Asia-Pacific region. <i>Archives of Osteoporosis</i> , 2018, 13, 59.	1.0	14
168	Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1784-1802.	2.0	14
169	Favorable skeletal benefit/risk of long-term denosumab therapy: A virtual-twin analysis of fractures prevented relative to skeletal safety events observed. <i>Bone</i> , 2020, 134, 115287.	1.4	14
170	Diagnostic Agreement at the Total Hip Using Different DXA Systems and the NHANES III Database. <i>Journal of Clinical Densitometry</i> , 2007, 10, 132-137.	0.5	13
171	Denosumab in postmenopausal osteoporosis: what the clinician needs to know. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2009, 1, 13-26.	1.2	13
172	Denosumab – an emerging treatment for postmenopausal osteoporosis. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 467-476.	1.4	13
173	Vitamin D and Common Sense. <i>Journal of Clinical Densitometry</i> , 2011, 14, 95-99.	0.5	13
174	Osteoporosis. <i>Annals of Internal Medicine</i> , 2011, 155, ITC1.	2.0	13
175	The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies. <i>Osteoporosis International</i> , 2019, 30, 71-78.	1.3	13
176	Core principles for fracture prevention: North American Consensus from the National Osteoporosis Foundation, Osteoporosis Canada, and Academia Nacional de Medicina de Mexico. <i>Osteoporosis International</i> , 2020, 31, 2073-2076.	1.3	13
177	Denosumab for joints and bones. <i>Current Rheumatology Reports</i> , 2009, 11, 196-201.	2.1	12
178	Bone Density Measurement and Assessment of Fracture Risk. <i>Clinical Obstetrics and Gynecology</i> , 2013, 56, 667-676.	0.6	12
179	Drug-induced osteoporosis: from Fuller Albright to aromatase inhibitors. <i>Climacteric</i> , 2015, 18, 39-46.	1.1	12
180	A comprehensive fracture prevention strategy in older adults: The European union geriatric medicine society (EUGMS) statement. <i>European Geriatric Medicine</i> , 2016, 7, 519-525.	1.2	12

#	ARTICLE	IF	CITATIONS
181	Diagnosis and Treatment of Osteoporosis Before and After Fracture: A Side-by-Side Analysis of Commercially Insured and Medicare Advantage Osteoporosis Patients. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017, 23, 735-744.	0.5	12
182	Romosozumab, clinical trials, and real-world care of patients with osteoporosis. <i>Annals of Translational Medicine</i> , 2020, 8, 974-974.	0.7	12
183	Response to "The Perspective of the International Osteoporosis Foundation on the Official Positions of the International Society for Clinical Densitometry," by John A. Kanis et al.. <i>Journal of Clinical Densitometry</i> , 2005, 8, 143-144.	0.5	11
184	Imaging Technologies for Assessment of Skeletal Health in Men. <i>Current Osteoporosis Reports</i> , 2013, 11, 1-10.	1.5	10
185	Stop the war on DXA!. <i>Annals of the New York Academy of Sciences</i> , 2018, 1433, 12-17.	1.8	10
186	Denosumab: A Promising Drug for the Prevention and Treatment of Osteoporosis. <i>Women's Health</i> , 2006, 2, 517-525.	0.7	9
187	Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect. <i>Core Evidence</i> , 2009, 4, 13.	4.7	9
188	High Cardiorespiratory Fitness Is Associated with Reduced Risk of Low Bone Density in Postmenopausal Women. <i>Journal of Women's Health</i> , 2016, 25, 1073-1080.	1.5	9
189	What we don't know about osteoporosis. <i>Journal of Endocrinological Investigation</i> , 2016, 39, 491-493.	1.8	9
190	Evaluating Patients for Secondary Causes of Osteoporosis. <i>Current Osteoporosis Reports</i> , 2022, 20, 1-12.	1.5	9
191	Impact of Using the Ultradistal Radius Region of Interest on Diagnostic Classification. <i>Journal of Clinical Densitometry</i> , 2004, 7, 143-152.	0.5	8
192	Monitoring pharmacological therapy for osteoporosis. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2010, 11, 261-273.	2.6	8
193	Long dosing intervals in the treatment of postmenopausal osteoporosis. <i>Current Medical Research and Opinion</i> , 2007, 23, 2617-2625.	0.9	7
194	A Clinician's Perspective on the Use of Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis. <i>Journal of Clinical Densitometry</i> , 2008, 11, 478-484.	0.5	7
195	Fracture Risk Assessment in Clinical Practice: T-scores, FRAX, and Beyond. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2010, 8, 101-112.	1.3	7
196	Combination therapy: the Holy Grail for the treatment of postmenopausal osteoporosis?. <i>Current Medical Research and Opinion</i> , 2011, 27, 1493-1497.	0.9	7
197	Bone Density Testing: Science, the Media, and Patient Care. <i>Current Osteoporosis Reports</i> , 2014, 12, 227-229.	1.5	7
198	The potential use of antisclerostin therapy in chronic kidney disease " mineral and bone disorder. <i>Current Opinion in Nephrology and Hypertension</i> , 2015, 24, 1.	1.0	7

#	ARTICLE	IF	CITATIONS
199	Evaluation of Quantitative Computed Tomography Cortical Hip Quadrant in a Clinical Trial With Rosiglitazone: A Potential New Study Endpoint. <i>Journal of Clinical Densitometry</i> , 2016, 19, 485-491.	0.5	7
200	Relationship Between Gastrointestinal Events and Compliance With Osteoporosis Therapy: An Administrative Claims Analysis of the US Managed Care Population. <i>Clinical Therapeutics</i> , 2016, 38, 1074-1080.	1.1	7
201	The Clinical Utility of Vertebral Fracture Assessment in Predicting Fractures. <i>Journal of Clinical Densitometry</i> , 2017, 20, 304-308.	0.5	7
202	Lessons learned with Bone Health TeleECHO: making treatment decisions when guidelines conflict. <i>Osteoporosis International</i> , 2019, 30, 2401-2406.	1.3	7
203	Pulse-echo Ultrasound Identifies Caucasian and Hispanic Women at Risk for Osteoporosis. <i>Journal of Clinical Densitometry</i> , 2021, 24, 175-182.	0.5	7
204	The evolution of fracture risk estimation. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 2098-2100.	3.1	6
205	Suicide affects all of us. <i>Lancet, The</i> , 2012, 379, 2316-2318.	6.3	6
206	Bone Density Testing Intervals and Common Sense. <i>Current Osteoporosis Reports</i> , 2012, 10, 217-220.	1.5	6
207	COVID-19, Medical Education, and Bone Health: Insights From Project ECHO. <i>Journal of Clinical Densitometry</i> , 2020, 23, 338-339.	0.5	6
208	Effective communication regarding risk of fracture for individuals at risk of fragility fracture: a scoping review. <i>Osteoporosis International</i> , 2022, 33, 13-26.	1.3	6
209	Denosumab for the Treatment of Postmenopausal Osteoporosis. <i>Women's Health</i> , 2009, 5, 15-22.	0.7	5
210	Operationalizing Treat-to-Target for Osteoporosis. <i>Endocrinology and Metabolism</i> , 2021, 36, 270-278.	1.3	5
211	New and Emerging Therapies for Osteoporosis. <i>Journal of Osteoporosis</i> , 2010, 2010, 1-2.	0.1	4
212	Evaluation of the Patient at Risk for Osteoporosis. , 2013, , 1481-1504.		4
213	Biological therapy: chronicling 15 years of progress. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 619-621.	1.4	4
214	Skeletal Imaging in Primary Hyperparathyroidism. , 2015, , 447-454.		4
215	Vitamin D and COVID-19: Is something better than nothing?. <i>Osteoporosis and Sarcopenia</i> , 2020, 6, 95-96.	0.7	4
216	Assessment of Skeletal Strength. <i>Endocrinology and Metabolism Clinics of North America</i> , 2021, 50, 299-317.	1.2	4

#	ARTICLE	IF	CITATIONS
217	Medications Don't Work If Patients Don't Take Them. Southern Medical Journal, 2007, 100, 1190-1191.	0.3	4
218	Three-year progress report of Bone Health TeleECHO Moscow: a strategy to improve the care of patients with osteoporosis and other metabolic skeletal diseases in underserved communities of Russia. Osteoporosis International, 2022, 33, 2035-2040.	1.3	4
219	The role of osteoanabolic agents in the management of patients with osteoporosis. Postgraduate Medicine, 2022, 134, 541-551.	0.9	4
220	Is It Ethical to Use Placebos in Osteoporosis Trials?. Journal of Clinical Densitometry, 2006, 9, 274-280.	0.5	3
221	FRIO289...Denosumab Treatment in Postmenopausal Women with Osteoporosis for Up to 9 Years: Results Through Year 6 of the Freedom Extension. Annals of the Rheumatic Diseases, 2015, 74, 529.2-530.	0.5	3
222	Clinical Vignettes: Using Non-BMD Measurements in Clinical Practice. Clinical Reviews in Bone and Mineral Metabolism, 2016, 14, 50-54.	1.3	3
223	Bone Density Testing Is the Best Way to Monitor Osteoporosis Treatment. American Journal of Medicine, 2017, 130, 1133-1134.	0.6	3
224	Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women. Annals of Internal Medicine, 2017, 167, 902.	2.0	3
225	Estimation of Long-Term Efficacy of Denosumab Treatment in Postmenopausal Women With Osteoporosis: A FRAX and Virtual Twin-Based Post Hoc Analysis From the FREEDOM and FREEDOM Extension Trials. JBMR Plus, 2020, 4, e10348.	1.3	3
226	Augmentation Procedures for Osteoporotic Vertebral Fractures—An Ongoing Experiment or Emerging Standard of Care?. Southern Medical Journal, 2006, 99, 449-450.	0.3	3
227	Racial Disparities and Inequalities in the Management of Patients With Osteoporosis. Orthopaedic Nursing, 2022, 41, 125-134.	0.2	3
228	Is denosumab better than alendronate in the treatment of osteoporosis?. Nature Clinical Practice Rheumatology, 2009, 5, 72-73.	3.2	2
229	Using FRAX® wisely: lessons from Switzerland and beyond. Nature Reviews Endocrinology, 2010, 6, 126-128.	4.3	2
230	Time to Reconsider. JAMA - Journal of the American Medical Association, 2011, 305, 1070.	3.8	2
231	Evaluation of the osteoporosis patient. , 2021, , 1475-1500.		2
232	Bone Health TeleECHO for Orthopedists and Rheumatologists. Orthopedics and Rheumatology Open Access Journal, 2017, 7, .	0.0	2
233	The current role of telehealth in the management of patients with osteoporosis. Expert Review of Endocrinology and Metabolism, 2022, 17, 245-254.	1.2	2
234	CBGC. JAMA - Journal of the American Medical Association, 1977, 237, 2472.	3.8	1

#	ARTICLE	IF	CITATIONS
235	Is alendronate therapy cost-effective for postmenopausal osteopenia?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2005, 1, 74-75.	2.9	1
236	Kyphosis and vertebral fractures: what do we know now?. <i>Aging Health</i> , 2009, 5, 483-487.	0.3	1
237	Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women. <i>Annals of Internal Medicine</i> , 2017, 167, 901.	2.0	1
238	Re: A History of Pivotal Advances in Clinical Research Into Bone and Mineral Diseases. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 1900-1901.	3.1	1
239	Fractures While Walking Leashed Dogs. <i>JAMA Surgery</i> , 2019, 154, 1078.	2.2	1
240	Phytoestrogens and Their Role in the Management of Postmenopausal Osteoporosis. <i>Southern Medical Journal</i> , 2009, 102, 111-112.	0.3	1
241	Preventing Fractures in Diabetic Dialysis Patients. <i>International Journal of Endocrinology and Metabolism</i> , 2011, 10, 640-641.	0.3	1
242	Denosumab: Mechanisms and Therapeutic Effects in the Treatment of Osteoporosis. <i>Contemporary Endocrinology</i> , 2020, , 309-322.	0.3	1
243	T-score as an Indicator of Fracture Risk on Therapy: Evidence From Romosozumab vs Alendronate Treatment in the ARCH Trial. , 2020, 29, .		1
244	Update on bone density testing. <i>Current Osteoporosis Reports</i> , 2005, 3, 136-142.	1.5	1
245	Whole Body, Whole Life, Whole Family: Patientsâ€™ Perspectives on X-Linked Hypophosphatemia. <i>Journal of the Endocrine Society</i> , 0, , .	0.1	1
246	Recommendations regarding individuals in whom bone densitometry should be performed: Comment on the article by van Staa et al. <i>Arthritis and Rheumatism</i> , 2004, 50, 2715-2716.	6.7	0
247	Update on osteoporosis. <i>Women's Health</i> , 2005, 1, 23-25.	0.7	0
248	Prevention of osteoporotic fractures. <i>Aging Health</i> , 2006, 2, 649-659.	0.3	0
249	MOBILE 2-Year. <i>Obstetrics and Gynecology</i> , 2006, 107, 91S-92S.	1.2	0
250	Relationships between bone mineral density and breast cancer risk (by Gail model) in postmenopausal women with low bone mass or osteoporosis. <i>Journal of Clinical Densitometry</i> , 2007, 10, S215.	0.5	0
251	Pharmacologic therapy to reduce fracture risk: comment on the clinical practice guidelines of the ACP. <i>Nature Reviews Rheumatology</i> , 2009, 5, 120-121.	3.5	0
252	Is It Time for Physicians to Focus on the Public Health Threat of Gun Violence?. <i>Annals of Internal Medicine</i> , 2013, 158, 851.	2.0	0

#	ARTICLE	IF	CITATIONS
253	SAT0463â€¦Effect of Eight Years of Denosumab Treatment in Postmenopausal Women with Osteoporosis: Five-Year Results from the Freedom Extension. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 761.2-761.	0.5	0
254	SAT0487â€¦Denosumab (DMAB) Effect on Bone Histology and Histomorphometry in Men with Low Bone Mineral Density (BMD): Table 1.. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 769.2-769.	0.5	0
255	Firearm-Related Injury and Death in the United States. <i>Annals of Internal Medicine</i> , 2015, 163, 323.	2.0	0
256	Letter to the Editor from Dreyer, et al: â€œOsteoporosis in Premenopausal Women: A Clinical Narrative Review by the ECTS and the IOFâ€• <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e1920-e1921.	1.8	0
257	Osteoporosis Management with Focus on Spine. , 2021, , 61-92.		0
258	Skeletal Health Prognostications. <i>Southern Medical Journal</i> , 2006, 99, 105-106.	0.3	0
259	Do Phytoestrogens Have a Role in the Management of Postmenopausal Osteoporosis?. <i>Southern Medical Journal</i> , 2008, 101, 2.	0.3	0
260	Targeting cathepsin K for the treatment of osteoporosis: Focus on odanacatib. <i>Drugs of the Future</i> , 2010, 35, 643.	0.0	0
261	Integrated Clinical View on Long-Term Management of Patients with Osteoporosis. , 2016, , 309-320.		0
262	Osteoporosis Treatment Success and Failure. , 2021, , 185-195.		0